Communiqués Glenmark Pharmaceuticals Limited

Actions

GLENMARK

INE935A01035

Produits pharmaceutiques

Temps Différé NSE India S.E. 08:36:56 13/10/2026			Varia. 5j.	Varia. 1 janv.
2 264,80 ^INR	-0,80 %		-2,03 %	+11,25 %

11/09	Glenmark Pharmaceuticals Limited propose un dividende pour l'exercice clos le 31 mars 2026	CI
07/09	Acucort obtient la protection de la marque Zeqmelit en Ukraine	FW

Communiqués

24/09	Glenmark Pharmaceuticals receives Establishment Inspection Report from U.S. FDA for its Goa facility with VAI classification	AQ
31/03	Glenmark Pharmaceuticals Canada Inc. Launches Men's GLN-Minoxidil 5% w/w Topical Aerosol Foam in Canadian Retail	AQ
04/03	Glenmark Pharmaceuticals : Specialty SA Receives U.S. FDA Approval for Fluticasone Propionate Inhalation Aerosol USP, 44 mcg per actuation, with 180-Day Competitive Generic Therapy Exclusivity	PU
27/02	Glenmark Pharmaceuticals : USA to launch Sodium Phosphates Injection USP, 15 mM P/5 mL, 45 mM P/15 mL and 150 mM P/50 mL (3 mM P/mL) Single-Dose Vials	PU
04/02	Glenmark Pharmaceuticals : Q3FY 2025-26	PU
30/01	Glenmark Pharmaceuticals : Q3 FY 2025-26	PU
23/12	Glenmark Pharmaceuticals : USA launches Epinephrine Injection USP, 30 mg/30 mL (1 mg/mL) Multiple-Dose Vial	PU
16/12	Glenmark Pharmaceuticals : Secures Exclusive Multi-Regional Rights to Aumolertinib, an MHRA and NMPA approved Third-Generation EGFR-TKI, from Hansoh Pharma	PU
11/12	Glenmark Pharmaceuticals : USA to launch Leucovorin Calcium for Injection USP, 350 mg/vial Single-Dose Vial	PU
27/11	Glenmark Pharmaceuticals : receives Establishment Inspection Report (EIR) from U.S. FDA for its Monroe facility	PU
25/11	Glenmark Pharmaceuticals : Announces Launch of Nebzmart GFB Smartules and Glenmark Airz FB Smartules, World’s First Nebulized Triple Therapy for COPD	PU
25/11	Glenmark Pharmaceuticals : Cosmo and Glenmark Announce Market Authorization of Winlevi (clascoterone) 10 mg/g cream for Treatment of Acne in 15 countries in Europe	PU
19/11	Cosmo and Glenmark Announce Market Authorization of Winlevi 10 mg/g cream for Treatment of Acne in 15 countries in Europe	AQ
19/11	Glenmark Pharmaceuticals : Q2FY 2025-26	PU
18/11	Glenmark Pharmaceuticals : Cosmo and Glenmark Announce Market Authorization of Winlevi (clascoterone) 10 mg/g cream for Treatment of Acne in 15 countries in Europe	PU
14/11	Glenmark Pharmaceuticals : Q2 FY 2025-26	PU
14/11	Glenmark Pharmaceuticals : Announces Q2FY26 Results	PU
10/11	Glenmark Pharmaceuticals : Secures China Approval For RYALTRIS, Reinforcing Respiratory Innovation Leadership	PU
04/11	Glenmark Pharmaceuticals : USA to launch 8.4% Sodium Bicarbonate Injection USP, 50 mEq/50 mL (1 mEq/mL) Single-Dose Vial	PU
23/10/25	Glenmark Pharmaceuticals : USA to launch Ropivacaine Hydrochloride Injection USP, 40 mg/20 mL (2mg/mL), 150 mg/30 mL (5 mg/mL), and 200 mg/20 mL (10 mg/mL) Single-Dose Vials	PU
24/09/25	Glenmark Pharmaceuticals : Strengthens Oncology Portfolio with Hengrui’s HER2 Targeting ADC For Multiple Regions	PU
02/09/25	Glenmark Pharmaceuticals : to launch Eribulin Mesylate Injection 1 mg-2 mL (0.5 mg-mL) Single-Dose Vials	PU
29/08/25	Glenmark Pharmaceuticals : FY 2024-25	PU
26/08/25	Glenmark Pharmaceuticals : Q1FY 2025-26	PU
19/08/25	Glenmark Pharmaceuticals : USA to launch Micafungin for Injection USP, 50 mg/vial and 100 mg/vial (Single-Dose Vial)	PU